Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT03663933 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03663933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03663933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 4, 2018
Completion date
April 3, 2030
Enrollment
71 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune lymphoproliferative, common variable immunodeficiency, immune system diseases, lymphoproliferative disorders, primary t-cell immunodeficiency disorders